Related Experiment Video
Updated: Nov 23, 2025

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Superficial Acral Fibromyxoma: A case report
Mürüvvet Akçay Çelik1, Havva Erdem1, Nurten Turhan Haktanır2
1Department of Medical Pathology, Faculty of Medicine, Ordu University, Ordu, Turkey.
Superficial Acral Fibromyxoma, a rare benign tumor, presents as a painful mass on digits. Surgical excision is the standard treatment for this slow-growing digital fibromyxoma.
Area of Science:
- Oncology
- Dermatopathology
- Surgical Pathology
Background:
- Superficial Acral Fibromyxoma (SAF) is a rare, benign soft tissue tumor, also known as digital fibromyxoma.
- Typically presents as a slow-growing, painful solitary mass on fingers, toes, or nail beds.
- Positive margins are frequently linked to local recurrence of SAF.
Observation:
- A case study involving a 54-year-old male with a two-lobed mass on the 5th finger of his right hand.
- The lesion was situated adjacent to the 5th finger flexor tendon.
- Excisional biopsy specimen was submitted for pathological examination.
Findings:
- Superficial Acral Fibromyxoma is classified as a rare benign myxoid neoplasm.
- The presented case highlights a typical manifestation of SAF in the acral region.
- Pathological analysis confirmed the diagnosis of Superficial Acral Fibromyxoma.
Implications:
- Surgical excision is the primary treatment modality for Superficial Acral Fibromyxoma.
- This case underscores the importance of considering SAF in the differential diagnosis of acral region neoplasms.
- Awareness of SAF's characteristics is crucial for accurate diagnosis and management of digital masses.
More Related Videos
07:58Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
Published on: November 23, 2017
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024